Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Nestle Health Science to acquire UK-based Phagenesis

Nestle Health Science to acquire UK-based Phagenesis

5th September 2016

Nestle Health Science has agreed a deal to acquire Phagenesis, a UK-based company dedicated to the treatment of dysphagia, or swallowing difficulties.

The staged, milestone-based acquisition will see Nestle Health Science make an upfront payment, followed by milestone-based funding, while Phagenesis completes the developments of Phagenyx, its lead product.

Phagenyx is an innovative pharyngeal electrical stimulation device that works by delivering an electrical signal optimised for each patient to the back of the throat, restoring neurological control of swallowing by kickstarting the reorganisation of the brain.

The staged acquisition will be based on the successful completion of clinical development programmes in Europe and the US, which are expected to take place by 2019.

Greg Behar, chief executive officer of Nestle Health Science, said: "Dysphagia is a strategic focus for Nestle Health Science. This innovation can bring a new dimension to swallowing rehabilitation that can be transformational from a patient and healthcare professional perspective."

Dysphagia is commonly experienced by post-stroke patients, but also the elderly and those undergoing post-mechanical ventilation in intensive care units.

With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801824773-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.